Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease
Leptomeningeal disease (LMD) is a serious cancer complication associated with poor prognosis.Approximately 5%–25% of patients with melanoma develop LMD.